<DOC>
	<DOC>NCT00738530</DOC>
	<brief_summary>This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is greater than (&gt;)500 individuals.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>metastatic renal cell cancer (clear cell type); nephrectomy; absence of proteinuria. prior systemic treatment for metastatic renal cell cancer; major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to study treatment start; presence of brain metastases or spinal cord compression; ongoing need for full dose anticoagulants; uncontrolled hypertension; clinically significant cardiovascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>